C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 34% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Press Release: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Stephens & Co. Initiates Coverage On C4 Therapeutics With Equal-Weight Rating, Announces Price Target of $4
C4 Therapeutics Analyst Ratings
Express News | C4 Therapeutics Inc Files for Stock Shelf Offering of up to $200 Mln - SEC Filing
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14